101 related articles for article (PubMed ID: 9287145)
21. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer.
Song K; Chang Y; Prud'homme GJ
Gene Ther; 2000 Mar; 7(6):481-92. PubMed ID: 10757021
[TBL] [Abstract][Full Text] [Related]
22. Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo.
Sarma S; Guo Y; Guilloux Y; Lee C; Bai XF; Liu Y
J Exp Med; 1999 Mar; 189(5):811-20. PubMed ID: 10049945
[TBL] [Abstract][Full Text] [Related]
23. Co-expression of P1A35-43/beta2m fusion protein and co-stimulatory molecule CD80 elicits effective anti-tumor immunity in the P815 mouse mastocytoma tumor model.
Zhang X; Mei W; Zhang L; Yu H; Zhao X; Fan X; Qian G; Ge S
Oncol Rep; 2009 Nov; 22(5):1213-20. PubMed ID: 19787242
[TBL] [Abstract][Full Text] [Related]
24. TNF-mediated toxicity after massive induction of specific CD8+ T cells following immunization of mice with a tumor-specific peptide.
Bilsborough J; Uyttenhove C; Colau D; Bousso P; Libert C; Weynand B; Boon T; van den Eynde BJ
J Immunol; 2002 Sep; 169(6):3053-60. PubMed ID: 12218121
[TBL] [Abstract][Full Text] [Related]
25. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.
Bour H; Horvath C; Lurquin C; Cerottini JC; MacDonald HR
J Immunol; 1998 Jun; 160(11):5522-9. PubMed ID: 9605156
[TBL] [Abstract][Full Text] [Related]
26. On the role of unmutated antigens in tumor rejection in mice with unperturbed T-cell repertoires.
Sarma S; Bai XF; Liu JQ; May KF; Zheng P; Liu Y
Cancer Res; 2003 Sep; 63(18):6051-5. PubMed ID: 14522934
[TBL] [Abstract][Full Text] [Related]
27. Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor.
Levraud JP; Pannetier C; Langlade-Demoyen P; Brichard V; Kourilsky P
J Exp Med; 1996 Feb; 183(2):439-49. PubMed ID: 8627157
[TBL] [Abstract][Full Text] [Related]
28. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones.
Maryanski JL; Boon T
Eur J Immunol; 1982 May; 12(5):406-12. PubMed ID: 6178608
[TBL] [Abstract][Full Text] [Related]
29. Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL.
Silla S; Fallarino F; Boon T; Uyttenhove C
Eur Cytokine Netw; 1999 Jun; 10(2):181-90. PubMed ID: 10400824
[TBL] [Abstract][Full Text] [Related]
30. H2-restricted recognition of cloned HLA class I gene products expressed in mouse cells.
Maryanski JL; Accolla RS; Jordan B
J Immunol; 1986 Jun; 136(12):4340-7. PubMed ID: 3086429
[TBL] [Abstract][Full Text] [Related]
31. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.
Yang G; Hellström KE; Hellström I; Chen L
J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183
[TBL] [Abstract][Full Text] [Related]
32. Minimal tolerance to a tumor antigen encoded by a cancer-germline gene.
Huijbers IJ; Soudja SM; Uyttenhove C; Buferne M; Inderberg-Suso EM; Colau D; Pilotte L; Powis de Tenbossche CG; Chomez P; Brasseur F; Schmitt-Verhulst AM; Van den Eynde BJ
J Immunol; 2012 Jan; 188(1):111-21. PubMed ID: 22140254
[TBL] [Abstract][Full Text] [Related]
33. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
Lynch DH; Daynes RA; Hodes RJ
J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
[TBL] [Abstract][Full Text] [Related]
34. Induction of high-grade tumor-specific immunity in a host using a cytotoxic T-lymphocyte clone specific for a stable tumor antigen on murine leukemia L1210.
Rahman SM; Kawashima K; Nakashima I; Nagase F
Cancer Res; 1988 Nov; 48(22):6450-4. PubMed ID: 3263189
[TBL] [Abstract][Full Text] [Related]
35. Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen.
Bright RK; Beames B; Shearer MH; Kennedy RC
Cancer Res; 1996 Mar; 56(5):1126-30. PubMed ID: 8640771
[TBL] [Abstract][Full Text] [Related]
36. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
37. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
Ley V; Langlade-Demoyen P; Kourilsky P; Larsson-Sciard EL
Eur J Immunol; 1991 Mar; 21(3):851-4. PubMed ID: 2009918
[TBL] [Abstract][Full Text] [Related]
38. Distinct patterns of cytolytic T-cell activation by different tumour cells revealed by Ca
Frick M; Mouchacca P; Verdeil G; Hamon Y; Billaudeau C; Buferne M; Fallet M; Auphan-Anezin N; Schmitt-Verhulst AM; Boyer C
Immunology; 2017 Feb; 150(2):199-212. PubMed ID: 27716898
[TBL] [Abstract][Full Text] [Related]
39. [Specifics anti-tumor immunity induced by gene immunization with ectopic hCGbeta encoding gene].
Wang LX; Wu J; Guan QD; Xiong SD
Zhonghua Zhong Liu Za Zhi; 2003 Jul; 25(4):316-9. PubMed ID: 12921555
[TBL] [Abstract][Full Text] [Related]
40. Specific lysis of murine cells expressing HLA molecules by allospecific human and murine H-2-restricted anti-HLA T killer lymphocytes.
Achour A; Begue B; Gomard E; Paul P; Sayagh B; Van Pel A; Levy JP
Eur J Immunol; 1986 Jun; 16(6):597-604. PubMed ID: 3522244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
